Valbiotis SAS - Asset Resilience Ratio
Valbiotis SAS (ALVAL) has an Asset Resilience Ratio of 45.67% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Valbiotis SAS (ALVAL) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Valbiotis SAS's Asset Resilience Ratio has changed over time. See ALVAL equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Valbiotis SAS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Valbiotis SAS worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €6.57 Million | 45.67% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €6.57 Million | 45.67% |
Asset Resilience Insights
- Very High Liquidity: Valbiotis SAS maintains exceptional liquid asset reserves at 45.67% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Valbiotis SAS Industry Peers by Asset Resilience Ratio
Compare Valbiotis SAS's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Beijing Sanyuan Foods Co Ltd
SHG:600429 |
Packaged Foods | 0.10% |
|
ORKLA ADR/1 NK 625
F:OKL0 |
Packaged Foods | 1.88% |
|
Tingyi (Cayman Islands) Holding Corp
F:TYG |
Packaged Foods | 5.13% |
|
The a2 Milk Company Ltd
AU:A2M |
Packaged Foods | 24.93% |
|
Zydus Wellness Limited
NSE:ZYDUSWELL |
Packaged Foods | 0.27% |
|
Shandong Bailong Chuangyuan Bio-Tech Co. Ltd.
SHG:605016 |
Packaged Foods | 0.71% |
|
Qianhe Condiment&Food Co Ltd
SHG:603027 |
Packaged Foods | 0.45% |
|
Xinjiang Guannong Fruit & Antler Group Co Ltd
SHG:600251 |
Packaged Foods | 0.69% |
Annual Asset Resilience Ratio for Valbiotis SAS (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Valbiotis SAS.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 45.67% | €6.57 Million ≈ $7.68 Million |
€14.39 Million ≈ $16.82 Million |
+5.34pp |
| 2024-12-31 | 40.33% | €7.91 Million ≈ $9.24 Million |
€19.61 Million ≈ $22.92 Million |
+32.62pp |
| 2023-12-31 | 7.70% | €2.57 Million ≈ $3.00 Million |
€33.31 Million ≈ $38.94 Million |
+5.71pp |
| 2022-12-31 | 1.99% | €541.00K ≈ $632.49K |
€27.17 Million ≈ $31.77 Million |
+0.09pp |
| 2021-12-31 | 1.90% | €541.00K ≈ $632.49K |
€28.48 Million ≈ $33.29 Million |
-1.24pp |
| 2020-12-31 | 3.14% | €660.00K ≈ $771.61K |
€21.00 Million ≈ $24.55 Million |
-8.98pp |
| 2019-12-31 | 12.12% | €1.82 Million ≈ $2.13 Million |
€15.02 Million ≈ $17.55 Million |
-73.47pp |
| 2018-12-31 | 85.59% | €10.19 Million ≈ $11.91 Million |
€11.91 Million ≈ $13.92 Million |
+2.21pp |
| 2017-12-31 | 83.38% | €10.60 Million ≈ $12.39 Million |
€12.71 Million ≈ $14.86 Million |
+50.80pp |
| 2016-12-31 | 32.57% | €529.00K ≈ $618.46K |
€1.62 Million ≈ $1.90 Million |
+1.94pp |
| 2015-12-31 | 30.63% | €355.01K ≈ $415.05K |
€1.16 Million ≈ $1.35 Million |
-- |
About Valbiotis SAS
Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia. The company offers supplements for immunity and vitality, health and wellbeing, metabolic and cardiovascular health, and beauty and physical comfort. It also develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; T… Read more